SLC25A18 and disease arising from reactivation of latent virus: Overall, the quadrivalent mRNA vaccine incorporating gB2, gC2, gD2, and gE2 provided strong protection against vaginal viral replication, genital herpes, and latent infection, while inducing durable and broad humoral and cellular immune responses.